Pulse Biosciences Inc ( (PLSE) ) has released its Q4 earnings. Here is a breakdown of the information Pulse Biosciences Inc presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Pulse Biosciences Inc., a bioelectric medicine company, specializes in nanosecond Pulsed Field Ablation technology, aiming to revolutionize soft tissue ablation and cardiac treatments. The company recently reported its financial results for the fourth quarter and full year of 2024, highlighting significant advancements in its clinical trials and strategic appointments. Key highlights include positive preliminary results from its thyroid nodule treatment study and advancements in its atrial fibrillation treatment programs. Financially, the company reported increased expenses due to expanded operations and stock-based compensation, resulting in a higher net loss compared to the previous year. Looking forward, Pulse Biosciences plans to initiate several clinical trials in 2025, focusing on the commercialization of its soft tissue ablation technology and further development of its cardiac treatment systems.